Results 1 to 10 of about 10,843 (242)

Trial of Deferiprone in Parkinson's Disease.

New England Journal of Medicine, 2022
BACKGROUND Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder.
D. Devos, J. Labreuche, O. Rascol, J. Corvol, A. Duhamel, Pauline Guyon Delannoy, W. Poewe, Y. Compta, N. Pavese, E. Růžička, P. Dušek, B. Post, B. Bloem, D. Berg, W. Maetzler, Markus Otto, M. Habert, S. Lehéricy, J. Ferreira, R. Dodel, C. Tranchant, A. Eusebio, S. Thobois, A. Marques, W. Meissner, F. Ory-Magne, U. Walter, R. D. de Bie, Miguel Gago, D. Vilas, J. Kulisevsky, C. Januário, M. Coelho, S. Behnke, P. Worth, K. Seppi, T. Ouk, Camille Potey, C. Leclercq, R. Viard, Grégory Kuchcinski, Renaud Lopes, J. Pruvo, P. Pigny, G. Garçon, O. Simonin, Jesse A. Carpentier, Anne-Sophie Rolland, D. Nyholm, C. Scherfler, J. F. Mangin, M. Chupin, R. Bordet, D. Dexter, C. Fradette, M. Spino, F. Tricta, S. Ayton, A. Bush, J. Devedjian, J. Duce, I. Cabantchik, L. Defebvre, D. Deplanque, C. Moreau   +64 more
semanticscholar   +12 more sources

Efficacy and safety of early‐start deferiprone in infants and young children with transfusion‐dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double‐blind, placebo‐controlled, clinical trial (START) [PDF]

American journal of hematology/oncology, 2023
Children with transfusion‐dependent thalassemia (TDT) require regular blood transfusions that, without iron‐chelation therapy, lead to iron‐overload toxicities.
Mohsen Saleh Elalfy, Mona Hamdy, Amira Adly, Fatma Soliman Elsayed Ebeid, Noemi Toiber Temin, Anna Rozova, David Lee, Caroline Fradette, Fernando Tricta   +8 more
openalex   +2 more sources

The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases [PDF]

Pharmaceuticals, 2023
The iron chelating orphan drug deferiprone (L1), discovered over 40 years ago, has been used daily by patients across the world at high doses (75–100 mg/kg) for more than 30 years with no serious toxicity.
George J. Kontoghiorghes
openalex   +2 more sources

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review [PDF]

Cureus, 2023
Despite the established efficacy of iron chelation therapy in transfusion-induced iron-overloaded patients, there is no universal agreement regarding the choice of an optimal chelating regimen.
Ahmed Salem, Payal Desai, Ahmed Elgebaly
openalex   +2 more sources

Mitochondrial ferritin upregulation by deferiprone reduced neuronal ferroptosis and improved neurological deficits via NDRG1/Yap pathway in a neonatal rat model of germinal matrix hemorrhage [PDF]

J Cereb Blood Flow Metab
Ferroptosis contributes to brain injury after germinal matrix hemorrhage (GMH). Mitochondrial ferritin (FTMT), a novel mitochondrial outer membrane protein, reduces oxidative stress in neurodegenerative diseases.
Ye Yuan, Xiao Yang, Yutong Zhao, Jerry J Flores, Lei Huang, Lingui Gu, Ruihao Li, Xingyu Zhang, Shiyi Zhu, Siyuan Dong, Hideki Kanamaru, Qiuguang He, Yihao Tao, Kun Yi, Mingyang Han, Xionghui Chen, Lei Wu, John H Zhang, Zongyi Xie, Jiping Tang   +19 more
semanticscholar   +2 more sources

Deferiprone ameliorates cisplatin induced peripheral neurotoxicity via ferritinophagy adjustment [PDF]

Sci Rep
Cisplatin-induced neurotoxicity is one of the limiting factors to its use especially in tumors that demand high drug dosage. One of the Cisplatin pathways is ferritinophagy which may end up in ferroptosis.
Hanan A. Seddiek, Mira Hanna, Amany Elsayed Mohamed Hamoud, M. Elbaset, Ahmed M A Akabawy, Mohamed Zakaria Kotb, Mohamed Mansour Khalifa   +6 more
semanticscholar   +2 more sources

DEVELOPMENT AND VALIDATION OF AN RP-HPLC METHOD FOR DEFERIPRONE ESTIMATION IN PHARMACEUTICAL DOSAGE FORM

Asian Journal of Pharmaceutical and Clinical Research, 2023
Objectives: For the simultaneous estimation of deferiprone in pharmaceutical formulations, a high-performance liquid chromatographic technique that is straightforward, reproducible, and effective was developed. Methods: The Advanced Technologies Ltd HPLC
Sachin Kothawade, VISHAL V PANDE
openalex   +3 more sources

Compare the Efficacy and Safety of Deferoxamine, Deferasirox, and Deferiprone in Patients With Sickle Cell Disease or Transfusion-Dependent Anemia: A Network Meta-Analysis of Randomized Control Trials [PDF]

Cureus
This network meta-analysis was conducted with the aim of comparing the efficacy and safety of deferiprone (DFP), deferasirox (DFX), and deferoxamine (DFO) in individuals with sickle cell disease (SCD) or transfusion-dependent anemia.
D. B. Arrey Agbor, Abhimanyu Karumanchi, Santoshini Adivi, Mohammed A Mohammed, Wajeeh Ur Rehman, Sandipkumar S Chaudhari, Thin M Soe, Neelum Ali   +7 more
semanticscholar   +2 more sources

Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects

International Journal of Molecular Sciences, 2023
The historical insights and background of the discovery, development and clinical use of deferiprone (L1) and the maltol–iron complex, which were discovered over 40 years ago, highlight the difficulties, complexities and efforts in general orphan drug ...
G. Kontoghiorghes
semanticscholar   +1 more source

Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by Deferiprone

PLoS Neglected Tropical Diseases, 2023
Iron is a trace metal element that is essential for the survival of cells and parasites. The role of iron in cerebral toxoplasmosis (CT) is still unclear.
Chong Wang, Linding Xie, Yien Xing, Min Liu, Jun Yang, Nannan Gao, Yihong Cai   +6 more
semanticscholar   +1 more source